View in EDS

Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

Saved in:
Bibliographic Details
Title: Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.
Authors: Budde LE; City of Hope National Medical Center, Duarte, California, United States., Kamdar M; Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, Colorado, United States., Assouline SE; Jewish General Hospital, McGill University, Canada., Chavez JC; Moffitt Cancer Center, Tampa, Florida, United States., Ghosh N; Levine Cancer Institute/Advocate Health, Wake Forest University School of Medicine, Charlotte, North Carolina, United States., Ollila TA; Brown University, Providence, Rhode Island, United States., Hodson DJ; Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Modi D; Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States., Bastos-Oreiro M; Gregorio Marañón Hospital/Gregorio Marañón Research Institute, Madrid, Spain., Naik SG; Penn State University College of Medicine, Hershey, United States., Nakhoda SK; Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States., Batlevi CL MD, PhD; Genentech, Inc., South San Francisco, California, United States., Wang J; Genentech, Inc., South San Francisco, California, United States., Makadia S; Genentech, Inc., South San Francisco, California, United States., Kwan A; Genentech, Inc., South San Francisco, California, United States., Penuel E; Genentech, Inc., South San Francisco, California, United States., Jing J; Genentech, Inc., South San Francisco, California, United States., Wu H; Genentech, Inc., South San Francisco, California, United States., Ead W; Genentech, Inc., South San Francisco, California, United States., Pham S; Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada., To I; Genentech, Inc., South San Francisco, California, United States., Wei MC; Genentech, Inc., South San Francisco, California, United States., Wang M; University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
Source: Blood [Blood] 2026 Apr 21. Date of Electronic Publication: 2026 Apr 21.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42013019
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Budde+LE%22">Budde LE</searchLink>; City of Hope National Medical Center, Duarte, California, United States.<br /><searchLink fieldCode="AU" term="%22Kamdar+M%22">Kamdar M</searchLink>; Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, Colorado, United States.<br /><searchLink fieldCode="AU" term="%22Assouline+SE%22">Assouline SE</searchLink>; Jewish General Hospital, McGill University, Canada.<br /><searchLink fieldCode="AU" term="%22Chavez+JC%22">Chavez JC</searchLink>; Moffitt Cancer Center, Tampa, Florida, United States.<br /><searchLink fieldCode="AU" term="%22Ghosh+N%22">Ghosh N</searchLink>; Levine Cancer Institute/Advocate Health, Wake Forest University School of Medicine, Charlotte, North Carolina, United States.<br /><searchLink fieldCode="AU" term="%22Ollila+TA%22">Ollila TA</searchLink>; Brown University, Providence, Rhode Island, United States.<br /><searchLink fieldCode="AU" term="%22Hodson+DJ%22">Hodson DJ</searchLink>; Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Modi+D%22">Modi D</searchLink>; Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States.<br /><searchLink fieldCode="AU" term="%22Bastos-Oreiro+M%22">Bastos-Oreiro M</searchLink>; Gregorio Marañón Hospital/Gregorio Marañón Research Institute, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Naik+SG%22">Naik SG</searchLink>; Penn State University College of Medicine, Hershey, United States.<br /><searchLink fieldCode="AU" term="%22Nakhoda+SK%22">Nakhoda SK</searchLink>; Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States.<br /><searchLink fieldCode="AU" term="%22Batlevi+CL+MD%2C+PhD%22">Batlevi CL MD, PhD</searchLink>; Genentech, Inc., South San Francisco, California, United States.<br /><searchLink fieldCode="AU" term="%22Wang+J%22">Wang J</searchLink>; Genentech, Inc., South San Francisco, California, United States.<br /><searchLink fieldCode="AU" term="%22Makadia+S%22">Makadia S</searchLink>; Genentech, Inc., South San Francisco, California, United States.<br /><searchLink fieldCode="AU" term="%22Kwan+A%22">Kwan A</searchLink>; Genentech, Inc., South San Francisco, California, United States.<br /><searchLink fieldCode="AU" term="%22Penuel+E%22">Penuel E</searchLink>; Genentech, Inc., South San Francisco, California, United States.<br /><searchLink fieldCode="AU" term="%22Jing+J%22">Jing J</searchLink>; Genentech, Inc., South San Francisco, California, United States.<br /><searchLink fieldCode="AU" term="%22Wu+H%22">Wu H</searchLink>; Genentech, Inc., South San Francisco, California, United States.<br /><searchLink fieldCode="AU" term="%22Ead+W%22">Ead W</searchLink>; Genentech, Inc., South San Francisco, California, United States.<br /><searchLink fieldCode="AU" term="%22Pham+S%22">Pham S</searchLink>; Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada.<br /><searchLink fieldCode="AU" term="%22To+I%22">To I</searchLink>; Genentech, Inc., South San Francisco, California, United States.<br /><searchLink fieldCode="AU" term="%22Wei+MC%22">Wei MC</searchLink>; Genentech, Inc., South San Francisco, California, United States.<br /><searchLink fieldCode="AU" term="%22Wang+M%22">Wang M</searchLink>; University of Texas MD Anderson Cancer Center, Houston, Texas, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227603509%22">Blood</searchLink> [Blood] 2026 Apr 21. <i>Date of Electronic Publication: </i>2026 Apr 21.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7603509 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1528-0020 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200064971%22">00064971 </searchLink><i>NLM ISO Abbreviation: </i>Blood <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42013019
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/blood.2025032422
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Mosunetuzumab plus polatuzumab vedotin in relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Budde LE
      – PersonEntity:
          Name:
            NameFull: Kamdar M
      – PersonEntity:
          Name:
            NameFull: Assouline SE
      – PersonEntity:
          Name:
            NameFull: Chavez JC
      – PersonEntity:
          Name:
            NameFull: Ghosh N
      – PersonEntity:
          Name:
            NameFull: Ollila TA
      – PersonEntity:
          Name:
            NameFull: Hodson DJ
      – PersonEntity:
          Name:
            NameFull: Modi D
      – PersonEntity:
          Name:
            NameFull: Bastos-Oreiro M
      – PersonEntity:
          Name:
            NameFull: Naik SG
      – PersonEntity:
          Name:
            NameFull: Nakhoda SK
      – PersonEntity:
          Name:
            NameFull: Batlevi CL MD, PhD
      – PersonEntity:
          Name:
            NameFull: Wang J
      – PersonEntity:
          Name:
            NameFull: Makadia S
      – PersonEntity:
          Name:
            NameFull: Kwan A
      – PersonEntity:
          Name:
            NameFull: Penuel E
      – PersonEntity:
          Name:
            NameFull: Jing J
      – PersonEntity:
          Name:
            NameFull: Wu H
      – PersonEntity:
          Name:
            NameFull: Ead W
      – PersonEntity:
          Name:
            NameFull: Pham S
      – PersonEntity:
          Name:
            NameFull: To I
      – PersonEntity:
          Name:
            NameFull: Wei MC
      – PersonEntity:
          Name:
            NameFull: Wang M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 21
              M: 04
              Text: 2026 Apr 21
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1528-0020
          Titles:
            – TitleFull: Blood
              Type: main
ResultId 1